Clinical Investigators' Financial Disclosures May Become Public Under FDA Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance, which includes many concepts recommended by HHS OIG, replaces document finalized in 2001.
You may also be interested in...
FDA's Financial Disclosure Requirements Might Extend To Comments On Citizen Petitions
Encouraging disclosure of any financial relationship with affected drug companies by those commenting on citizen petitions could be one way FDA could respond to a Senate report questioning tactics by Sanofi-Aventis in seeking to delay approval of a generic version of Lovenox (enoxaparin sodium injection), the firm's low molecular weight heparin.
FDA's Financial Disclosure Requirements Might Extend To Comments On Citizen Petitions
Encouraging disclosure of any financial relationship with affected drug companies by those commenting on citizen petitions could be one way FDA could respond to a Senate report questioning tactics by Sanofi-Aventis in seeking to delay approval of a generic version of Lovenox (enoxaparin sodium injection), the firm's low molecular weight heparin.
FDA Oversight Of Clinical Investigators’ Financials Still Lacking, OIG Finds
Clinical investigators may not be disclosing all financial interests in submissions to FDA, according to an Office of Inspector General report